ASCO 2023 | The possible benefits of tumor-informed MRD for patients with sarcoma

Junqiang Yin, MD, PhD, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, explains how most patients with sarcoma may benefit from tumor-informed minimal residual disease (MRD). Patients who are MRD positive tend to have a worse prognosis than those who are MRD negative. Tumor-informed MRD has a leading time of three months compared with conventional techniques, such as imaging, where CT/MRI guide the assessment of treatment. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.